Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study

ABSTRACT:

SUBMITTER: Auclin E 

PROVIDER: S-EPMC12337063 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature